Regulatory literacy · document reading
Sermorelin regulatory context: why a compounding-list entry is not a finished-product approval
Regulatory documents use precise categories. A substance appearing in a compounding-related document does not automatically establish that every product, route, claim, or use has been approved.
Read the document’s purpose before reading the name
The FDA’s March 2025 document addresses bulk drug substances nominated for use in compounding under section 503B. It explains the categories in the document and lists sermorelin acetate in Category 1, described there as bulk drug substances under evaluation. The document itself also describes other statutory and compounding conditions.
That context matters. A category in a bulk-substance list answers a compounding-policy question. It does not, by itself, equal approval of a finished drug product, prove suitability for an individual, or establish that a particular commercial formulation meets a regulatory standard.
Avoid category-to-claim shortcuts
Regulatory language is often misread when a document’s category label is lifted out of its purpose. A careful reader checks the agency, document date, statutory section, definition, and any conditions or exclusions before using the record to describe a product or claim.
This is the same discipline used throughout the site: the source has a scope. A document about bulk substances and compounding cannot be converted into a general statement that a product is approved, clinically established, or appropriate for a reader.
Keep the page informational
This page does not recommend or describe use, dosing, administration, treatment, or sourcing. It is intended to help readers recognize the difference between a substance name in a regulatory document and a finished-product authorization decision.
For current and jurisdiction-specific information, readers should use the applicable regulator’s own searchable records and product documents. The most accurate public claim is often the narrowest one: what the document actually says, when it said it, and what it does not decide.
Regulatory categories should be read in their own words
A regulatory source may describe an ingredient, a compounding category, a legal condition, a safety communication, a historical record, or a finished-product authorization. These categories have different meanings, and one should not be substituted for another because a simplified label sounds more conclusive. The original agency wording, jurisdiction, date, and linked document determine what the record actually says.
A page about regulatory context should also resist turning a record into individual advice. The fact that a database contains a term does not establish personal suitability, quality of a specific item, or a recommendation to obtain or use anything. The useful reader question is narrower: what category did the authority describe, and what does that category leave unanswered?